Tango Therapeutics files new $400 million at-the-market equity offering with Leerink Partners

Tango Therapeutics filed a prospectus supplement on August 11, 2026 for the sale of up to $400,000,000 in common stock through Leerink Partners LLC acting as sales agent under an existing sales agreement dated November 21, 2025. The company said it is terminating a prior prospectus supplement covering up to $100,000,000 in shares and will not sell further stock under it, replacing it with this new filing covering up to $400,000,000 in offerings under the same sales agreement.¹ Tango had sold approximately $64,389,566 of shares under the terminated prior supplement.¹ Leerink Partners is entitled to a commission of up to 3.0% of the gross sales price of shares sold.¹

Shares closed at $27.67 on Nasdaq on August 10, 2026.¹

The filing also updates investors on clinical progress. In June 2026, Tango reported initial safety and efficacy data from its ongoing Phase 1/2 trial testing vopimetostat alongside Revolution Medicines' RAS(ON) inhibitors in patients with pancreatic cancer that carries both an MTAP deletion and a RAS mutation, as well as in similarly defined lung cancer patients.¹ As of a May 28, 2026 cutoff, the trial had dosed 59 patients with previously treated disease across the two RAS-mutant, MTAP-deleted cancer types, split between combinations using daraxonrasib (20 pancreatic, 5 lung) and zoldonrasib (34 pancreatic).¹

In the daraxonrasib combination, response-evaluable pancreatic patients showed an objective response rate of 92% (11 of 12), a 90% six-month progression-free survival rate and 100% disease control rate, while lung cancer patients had a 100% ORR.¹ The zoldonrasib combination showed a 52% ORR, 74% six-month PFS and 96% disease control rate among 27 evaluable pancreatic patients.¹ Based on these results, Tango said it intends to move the daraxonrasib combination into Phase 3 testing for front-line MTAP-deleted pancreatic cancer, pending regulatory feedback.¹